Onc.AI accelerates precision oncology with the Valohai MLOps platform and Oracle Cloud
Onc.AI runs the Valohai platform on OCI’s powerful A10 GPUs to speed up biomarker development, cut deep learning costs by 50%, and enhance compliance.
United States | Healthcare
“With Oracle Cloud’s A10 GPUs powering our Valohai workflows, we’ve doubled the speed of our biomarker training and validation while reducing costs by 50%. This combination of performance, efficiency, and compliance gives us the confidence to rapidly innovate and bring AI-driven advances into oncology practice.”
Onc.AI is a precision oncology company revolutionizing cancer care by developing advanced imaging biomarkers that help oncologists and pharmaceutical researchers predict patient survival and treatment responses. The company’s mission relies on analyzing thousands of longitudinal CT scans—a challenge requiring massive compute resources, rigorous compliance controls, and cost-effective operations. With its previous infrastructure, limited access to high performance GPUs restricted scalability and increased the costs of training and validating complex deep learning models. To address these barriers, Onc.AI deployed the Valohai enterprise MLOps platform on Oracle Cloud Infrastructure (OCI) and transitioned its workflows to OCI’s A10 GPU instances. The move has doubled the company’s biomarker pipeline speed and reduced training run costs by 50% compared with its previous GCP T4 GPUs, all while facilitating clinical-ready compliance, flexible distributed cloud deployment, and simplified operational overhead. OCI AI infrastructure enables Onc.AI to move from experimentation to clinical deployment rapidly and securely, helping the company deliver solutions that empower clinicians and pharma partners to make timely, data-informed decisions, accelerate drug development, and enhance patient outcomes.